Enfortumab Vedotin Plus Pembrolizumab Shows a High Confirmed Objective Response Rate in First-Line Treatment of Cisplatin-Ineligible Patients with Advanced Urothelial Cancer
Findings from the EV-103 randomised Cohort K
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1650 results
EMA Recommends Extension of Therapeutic Indications for Sacituzumab Govitecan
New indication concerns the treatment of patients with advanced HR-positive, HER2-negative breast cancer who have received endocrine-based therapy, and at least two additional systemic therapies in the advanced setting
Perioperative Nivolumab Plus Chemotherapy Results in Higher pCR and Longer Survival in Patients with Resectable Stage IIIA or IIIB NSCLC
Findings from the NADIM II study
Newly Developed International Childhood Cancer Core Outcome Set Represents Physical, Psychosocial, and Neurocognitive Outcomes for 17 Common Childhood Cancer Subtypes
A set of core outcomes developed by the International Childhood Cancer Outcome Project
PRO Data Can Help When Deciding Between Neoadjuvant FOLFOX or Fluorouracil-Based Chemoradiation for Locally Advanced Rectal Cancer
Patient reported outcomes from the PROSPECT study
EMA Recommends Extension of Therapeutic Indications for Trifluridine/Tipiracil
New indication concerns the third-line treatment of metastatic colorectal cancer in combination with bevacizumab
FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
Evidence for efficacy is based on the results from the TALAPRO-2 study
Trastuzumab Deruxtecan in Second-Line Treatment for Patients with HER2-positive Advanced Gastric or Gastro-Oesophageal Junction Cancer
Findings from the DESTINY-Gastric02 study
Utility of a Methylation-Based Multicancer Early Detection Test in Identifying Whom with Symptoms to Investigate for Cancer
Findings from the SYMPLIFY study
Camonsertib in Patients with Advanced Solid Tumours Harbouring Loss of Function Alterations in DDR Genes
Findings from the TRESR study
Stopping Treatment Is a Reasonable Strategy for Patients with Advanced NSCLC Who Are Progression-Free to Front-Line ICI at 2 Years
Findings from a retrospective cohort study
Neoadjuvant Nivolumab Plus Ipilimumab is Safe and Orchestrates de novo Immune Responses in Patients with Cervical Squamous Cell Carcinoma
Findings from the COLIBRI study